

# Postoperative Nausea and Vomiting

---

LaBar, Amanda Lynn

Master's thesis / Diplomski rad

2024

Degree Grantor / Ustanova koja je dodijelila akademski / stručni stupanj: **University of Zagreb, School of Medicine / Sveučilište u Zagrebu, Medicinski fakultet**

Permanent link / Trajna poveznica: <https://um.nsk.hr/um:nbn:hr:105:048161>

Rights / Prava: [In copyright](#)/[Zaštićeno autorskim pravom.](#)

Download date / Datum preuzimanja: **2025-03-13**



Repository / Repozitorij:

[Dr Med - University of Zagreb School of Medicine Digital Repository](#)



UNIVERSITY OF ZAGREB  
SCHOOL OF MEDICINE

AMANDA LABAR

**Postoperative Nausea and Vomiting**

GRADUATE THESIS



Zagreb, 2024

This graduate thesis was made at the Department of Anesthesiology, Reanimatology and Intensive Care, University Hospital Centre, Zagreb School of Medicine, University of Zagreb, mentored by Professor Vilena Vrbanović Mijatović, MD, PhD. It was submitted for evaluation in the academic year of 2023/2024.

## Abbreviations

<b>5-HT3</b>	Serotonin receptor
<b>BBB</b>	Blood-brain barrier
<b>CNS</b>	Central nervous system
<b>CTZ</b>	Chemoreceptor trigger zone
<b>D2</b>	Dopamine receptor
<b>GABA<sub>A</sub></b>	$\gamma$ -Aminobutyric acid type A receptor
<b>H1</b>	Histamine receptor
<b>IV</b>	Intravenously
<b>M1</b>	Muscarinic receptor
<b>NK 1</b>	Neurokinin 1 receptor
<b>NTS</b>	Nucleus of the solitary tract
<b>PNS</b>	Peripheral nervous system
<b>PO</b>	“Per os” meaning by mouth
<b>PONV</b>	Postoperative Nausea and Vomiting
<b>POVOC</b>	Postoperative Vomiting in Children score
<b>TIVA</b>	Total Intravenous Anesthesia
<b>VPOP</b>	Vomiting in the Postoperative Period score

## TABLE OF CONTENTS

ABBREVIATIONS .....	III
SUMMARY .....	1
SAŽETAK .....	2
INTRODUCTION .....	3
RISK FACTORS .....	3
<i>Table 1</i> .....	4
<i>Table 2</i> .....	4
<i>PATIENT RISK FACTORS</i> .....	4
<i>ANESTHETIC RISK FACTORS</i> .....	5
<i>SURGICAL RISK FACTORS</i> .....	6
<i>PONV RISK SCORES</i> .....	6
<i>RISK SCORES FOR ADULTS</i> .....	7
<i>Table 3</i> .....	7
<i>Table 4</i> .....	8
<i>RISK SCORES FOR CHILDREN</i> .....	8
PATHOGENESIS.....	8
<i>CHEMORECEPTOR TRIGGER ZONE</i> .....	9
<i>HIGHER CORTICAL AREAS</i> .....	9
<i>VESTIBULAR INPUT</i> .....	9
<i>VAGAL INPUTS</i> .....	10
<i>RESPONSE</i> .....	10
PHARMACOLOGICAL TREATMENT .....	10
<i>ANTIEMETICS</i> .....	11
<i>SEROTONIN RECEPTOR ANTAGONISTS</i> .....	11
<i>GLUCOCORTICOIDS</i> .....	12
<i>ANTICHOLINERGICS</i> .....	13
<i>ANTIDOPAMINERGICS</i> .....	13
<i>NEUROKININ 1 RECEPTOR ANTAGONISTS</i> .....	13
<i>ANTIHISTAMINES</i> .....	14
<i>PHENOTHIAZINES</i> .....	14
<i>SEDATIVES</i> .....	14
<i>COMBINATION THERAPY</i> .....	15
NON-PHARMACOLOGICAL TREATMENT .....	15
<i>ACUPRESSURE</i> .....	16
<i>Figure 1</i> .....	16
<i>ACUPUNCTURE</i> .....	17
<i>GINGER</i> .....	17
<i>HYDRATION</i> .....	18
<i>AROMATHERAPY</i> .....	18
COMPLICATIONS.....	18
<i>DEHYDRATION</i> .....	19
<i>ELECTROLYTE DISTURBANCES</i> .....	19
<i>ALKALOSIS</i> .....	19

<i>ASPIRATION</i> .....	19
<i>WOUND DAMAGE</i> .....	20
PREVENTION .....	20
<i>Figure 2</i> .....	21
<i>PREVENTION IN ADULTS</i> .....	21
<i>ANTIEMETICS IN ADULTS</i> .....	22
<i>PREVENTION IN CHILDREN</i> .....	22
<i>ANTIEMETICS IN CHILDREN</i> .....	23
<i>AVOIDANCE OF VOLATILE ANESTHETICS</i> .....	23
<i>MINIMIZING OPIOIDS</i> .....	23
<i>HYDRATION</i> .....	23
FUTURE DIRECTIONS .....	24
<i>GENETICS</i> .....	24
<i>NERVE STIMULATION</i> .....	25
CONCLUSION.....	26
ACKNOWLEDGEMENTS.....	28
REFERENCES .....	29
BIOGRAPHY .....	45

## **Summary**

**Title:** Postoperative Nausea and Vomiting

**Author:** Amanda Lynn LaBar

**Keywords:** Postoperative nausea and Vomiting, PONV, surgery, anesthesia, risk factors, vomiting center, APFEL score

A comprehensive review of postoperative nausea and Vomiting (PONV) is presented, a widely recognized side effect occurring within the first 24 hours following a surgical procedure. This review aims to identify the factors influencing PONV, including patient-specific traits, anesthetic methods, and surgical interventions. It explains the neural pathways controlling vomiting and evaluates pharmacological and non-pharmacological approaches to managing PONV. Additionally, this thesis highlights the consequences associated with PONV and the importance of preventive measures tailored to individual risk profiles. It explores various methods in PONV management, including genetic investigations and nerve stimulation techniques, to improve patient outcomes and satisfaction. It emphasizes the complex nature of PONV, the significance of understanding contributing factors such as patient characteristics, anesthetic techniques, and surgical procedures, and the roles of pharmacological and non-pharmacological interventions in managing PONV.

## **Sažetak**

**Naslov:** Postoperativna Mučnina i Povraćanje

**Autor:** Amanda Lynn LaBar

**Ključne riječi:** Postoperativna mučnina i povraćanje, PONV, operacija, anestezija, faktori rizika, centar za povraćanje, APFEL rezultat

Prikazan je opsežan pregled postoperativne mučnine i povraćanja (PONV), široko poznate nuspojave koja se javlja unutar prva 24 sata nakon kirurškog zahvata. Ovaj pregled ima za cilj identificirati čimbenike koji utječu na PONV, uključujući osobine specifične za pacijenta, metode anestezije i kirurške intervencije. Objašnjava neuralne putove koji kontroliraju povraćanje i procjenjuje farmakološke i nefarmakološke pristupe liječenju PONV-a. Dodatno, u radu se naglašavaju posljedice povezane s PONV-om i važnost preventivnih mjera prilagođenih individualnim profilima rizika. Istražuje različite metode zbrinjavanja PONV-a, uključujući genetske pretrage i tehnike stimulacije živaca, kako bi se poboljšali ishodi i zadovoljstvo pacijenata. Naglašava složenu prirodu PONV-a, važnost razumijevanja čimbenika koji doprinose kao što su karakteristike bolesnika, tehnike anestezije i kirurški postupci te ulogu farmakoloških i nefarmakoloških intervencija u liječenju PONV-a.



## **Introduction**

Postoperative nausea and Vomiting (PONV) refers to nausea, retching, and vomiting within the first 24-48 postoperative hours (1). PONV is a widely recognized side effect during the postoperative recovery phase. Two of the most frequently encountered adverse events following surgery are nausea and vomiting. (2). In the general surgical population, it's estimated that around 30% experience this, though those with known risk factors may face significantly higher rates, potentially reaching up to 80%. (3, 4).

In modern healthcare settings, patient mortality due to PONV is low (5). Although patient mortality from PONV is low, PONV greatly influences patient well-being, impacting patient recovery duration and overall health outcomes (6). PONV can induce discomfort and distress, thereby impacting the overall surgical experience for patients (7). If not addressed, PONV may cause complications such as dehydration, electrolyte imbalances, and harm to surgical sites (8). Complications from PONV can result in prolonged recovery times, increased risk of further complications, and harm to the patient. Effective management of PONV is crucial for improving surgical outcomes, reducing hospital stays, and enhancing overall postoperative patient care quality. By implementing preventive strategies and tailoring anesthetic approaches to meet each patient's specific needs, anesthesiologists play a vital role in lowering the risk of PONV.

## **Risk Factors**

PONV impacts approximately 30% of children and adults following anesthesia (9,10). However, incidence significantly differs among individuals, with rates soaring as high as 80% in high-risk populations (4,9,10) Certain factors contribute to the variability in the occurrence of PONV. For example, patient characteristics, anesthetic selection, and the complexity of the surgery contribute to the variability in the occurrence of PONV. (Table 1-2)

Table 1  
*General Risk factors for PONV (4)*

<b>Patient-specific risk factors:</b>
Female gender
Nonsmoking status
History of PONV/motion sickness
<b>Anesthetic risk factors:</b>
Use of volatile anesthetics
Use of nitrous oxide
Use of intraoperative and postoperative opioids
<b>Surgical risk factors:</b>
Duration of surgery (each 30-min increase in duration increases PONV risk by 60%, so that a baseline risk of 10% is increased by 16% after 30 min)
Type of surgery

Table 2  
*Risk Factors for the Occurrence of PONV in Pediatric Patients (11)*

<b>Surgical</b>	Duration greater than 30 minutes Ocular surgery ENT surgery (adenoidectomy, tonsillectomy)
<b>Anesthetic</b>	Use of volatile anesthetic Use of opioids Increased postoperative pain
<b>Patients</b>	Age of >3 years History or immediate family history Prolonged preoperative fast State of dehydration

Patient Risk Factors

In general, there are four patient-specific risk factors: 1) female gender, 2) smoking status, 3) age, and 4) history of PONV/motion sickness (4,12). The gender risk factor becomes significant after puberty, with females having a higher risk of experiencing PONV (4,13). In adults, being female is a strong predictor, with females being 2 to 4 times more likely to develop PONV (4,9,10,11,12). The authors found that the female gender was the strongest patient-specific

predictor, followed by the history of PONV and motion sickness (12). Nonsmokers are more prone to PONV compared to smokers (12). Children aged three years and older have a higher risk of PONV compared to those younger than 3 (11,14). Adults aged between 18 and 50 are considered a risk factor while increasing age has been shown to slightly decrease the risk of PONV (11,15). A personal history of PONV and motion sickness in adults and children has been identified as a risk factor (9,10,11). Children are more likely to experience symptoms if one of their family members has also experienced PONV (16). Often overlooked, preoperative anxiety is also a significant risk factor in children undergoing surgery, as the fear experienced before a procedure can trigger physiological responses contributing to PONV (11,17). Activation of the sympathetic nervous system due to anxiety results in elevated secretion of stress hormones, disturbs gastrointestinal motility, and delays gastric emptying (17).

#### Anesthetic Risk Factors

The choice of anesthetic also influences the risk of PONV (4,18). Different anesthetics have varying effects on the patient. (4,18). In contrast to general anesthesia, regional anesthesia has been found to reduce the risk of PONV in children and adults (19). Volatile anesthetics, such as sevoflurane, are associated with a higher risk of PONV as compared to total intravenous anesthesia using Propofol (20). A meta-analysis revealed a significant reduction in PONV in adults and children who received Propofol, showing a 5.7 decrease in adults and a 3.5 decrease in children (21). Nitrous oxide has also been shown to increase the risk of PONV in high-risk adults and children (9,10, 22, 23) The duration of anesthesia is also a contributing factor. Longer durations with volatile anesthetics correlate with higher risk, as more prolonged procedures require higher dosages, thereby increasing the risk to the patient (4,24). Furthermore, specific procedures known to be painful and require high doses of opioids can further elevate the risk of PONV (12).

### Surgical Risk Factors

Many surgical procedures are known to increase the risk of PONV (4,11). For example, procedures on the upper airway, nose, throat, oral, pharyngeal, esophageal, and stomach in which blood is swallowed, or bleeding occurs within the GI tract are known to increase the risk of PONV (5). Procedures such as tonsillectomy, adenoidectomy, strabismus, and orchidopexy surgeries have been associated with a higher incidence of PONV in pediatric patients (11). As noted above, the length of the surgery also contributes to an increased risk, with studies showing a 60% rise in risk for every additional 30 minutes of operating time (9,10). In adults, specific procedures involving sensitive anatomical structures such as breast, gynecological, eye, and ear surgeries (due to vestibular system involvement) and neurosurgeries are also linked to heightened PONV risk (9). Moreover, procedures expected to cause significant postoperative pain also increase the risk of PONV (4,9).

### PONV Risk Scores

Treatment and prevention of PONV requires accurate risk stratification (25). Numerous scoring systems have been developed to predict a patient's risk of experiencing PONV (28,29,26). Some of the more notable scoring systems are the Apfel, Koivuranta, and Palazzo & Evans (27,28,29). The PONV scoring systems were developed using logistic regression modeling (27). In general, the PONV scoring systems consider various factors, including, but not limited to, patient characteristics, anesthetic choices, and surgical procedures (10).

### Risk Scores for Adults

Initially proposed by Apfel and colleagues in 1999, the APFEL scoring system is commonly used in predicting the risk of PONV in adult patients (25, 28, 29, 30). The formula and original scoring system were developed using a multivariable logistic regression analysis (29). The scoring system was further simplified to a four-factor risk score, determined by the number of predictors present (29). The APFEL scoring system is simple, feasible, and the most adequate tool for assessing a patient's risk of PONV (29,31). Numerous groups have already implemented the APFEL scoring system in their daily practice (26,29). In a 2023 study, the authors indicated that the overall cost of prevention and treatment for PONV was less when the APFEL scoring system was used (32). In a 2015 prospective study, the authors concluded that the APFEL scoring system is a simple and reliable test to identify patients at high risk and can thus be used for preventative treatment strategies (29).

The APFEL scoring system defines PONV as at least one episode of nausea and Vomiting within the first 24 hours after surgery (29). The APFEL scoring system assigns a single point for each of the four risk factors: female sex, non-smoking status, personal history of PONV and motion sickness, and opioid use either intraoperatively or postoperatively (Table 3). The total score, ranging from 0 to 4, correlates with the predicted risk of PONV (28,29). Each APFEL risk factor is supposed to elevate the incidence of PONV by about 20% (28,29).

Table 3  
*Simplified APFEL Risk Scoring System (29)*

<b>Risk factors</b>	<b>Points</b>
Female gender	1
Nonsmoker	1
History of PONV	1
Postoperative opioids	1
Total Points	0-4

APFEL scores of 0-1 are generally considered low risk, while those of 3-4 denote high risk, often prompting the use of multiple antiemetic agents (28,29). As seen below, Table 4 illustrates the APFEL point values followed by their corresponding levels of risk.

*Table 4*  
*APFEL Levels of Risk (28)*

<i>Points</i>	<i>Level of Risk</i>
<b>0-1</b>	Low risk for PONV
<b>2</b>	Moderate risk for PONV
<b>3-4</b>	High risk for PONV

*Risk Scores for Children*

In the pediatric population, there are two risk-scoring systems commonly used by healthcare providers to assess the risk of PONV. (34,36) The first system used to predict the risk of PONV in children is known as the Postoperative Vomiting in Children score (POVOC). The second system to predict PONV in children is the vomiting in the Postoperative Period score (VPOP). (34,36) Leopold H. Eberhart developed the POVOC score, which consists of four variables, each assigned a score of 1 (34). Eberhart’s variables include undergoing strabismus surgery, being three years of age, having a duration of surgery longer than 30 minutes, and having a history of PONV (35). On the other hand, the VPOP score also considers the administration of multiple doses of opioids (36).

**Pathogenesis**

The regulation of vomiting is controlled by the vomiting center, located in a region of the brainstem called the medulla oblongata (37). This center receives inputs from various parts of the body, including higher brain centers, the vestibular system, the chemoreceptor trigger zone, and the nucleus tractus solitarii (NTS) (38). The four primary pathways transmit signals to the vomiting

center, triggering nausea and vomiting. Five primary neurotransmitter receptors are involved in the mediation of nausea and vomiting: muscarinic (M1), dopamine (D2), histamine (H1), serotonin (5-HT3), and neurokinin 1 (NK1) receptors associated with substance P. Every receptor serves as a prospective target for the prevention and treatment of PONV (10).

### Chemoreceptor Trigger Zone

The chemoreceptor trigger zone (CTZ) is within the brainstem, specifically in the medulla, known as the area postrema, located at the base of the fourth ventricle (8). This region lies outside the blood-brain barrier (BBB) and features fenestrated capillaries (10). Fenestrated capillaries allow the sampling of particles in the peripheral blood by the CTZ. The CTZ contains a variety of receptors, including opioids, NK1, M1, 5-HT3, D2, and H1 receptors (10). The receptors exhibit sensitivity to neurotransmitters and substances, thereby contributing to the CTZ's ability to detect stimuli and coordinate the initiation of nausea and vomiting.

### Higher Cortical Areas

The cortex processes information from various sources, including thoughts, sights, smells, pain, memory, and fear (39). The cortex then transmits the signals to higher brain centers, eventually reaching the vomiting center (40). A recent systematic review on reducing pain after breast surgery found conclusive evidence that loco-regional blocks (specifically paravertebral and pectoralis blocks) and glucocorticoids led to a significant relative reduction in the incidence of PONV by 70% (41) This 70% reduction in PONV incidence contributes to improved postoperative outcomes for breast surgery patients (41).

### Vestibular Input

Vestibular input, including motion sickness, is transmitted through cranial nerve eight, the vestibulocochlear nerve, conveying information that undergoes processing in the cerebellum (8,

42). The processed signal then travels to the vomiting center, which triggers the vomiting reflex. This pathway involves the H1 and M1 receptors.

### Vagal Inputs

Direct stimulation of the gastric mucosa triggers the release of substance P and serotonin from enterochromaffin cells in the stomach (43). The cells activate the vagus nerve and 5-HT3 splanchnic nerves, transmitting signals to the NTS and relaying the signals to the vomiting center (8). A 2021 study examined whether the gut-vagus-brain reflex mediates PONV (44). Among the 3,223 patients undergoing vagus nerve trunk resection or non-vagotomy surgery in the study, PONV occurred less in vagotomy patients (11.9%) than in non-vagotomy patients (28.7%) (44). This finding suggests that vagus nerve-dependent gut-brain signaling may primarily contribute to PONV (44).

### Response

Stimulation of the vomiting center triggers a series of responses, including the contraction of the smooth muscle lining the digestive tract and the abdominal muscles, relaxation of the esophageal sphincter, and stimulation of the salivary glands (8). This series of responses leads to the involuntary and forceful expulsion of stomach contents from the mouth.

## **Pharmacological Treatment**

The pharmacological management of PONV entails administering medications to relieve or prevent symptoms of nausea and vomiting by targeting specific receptors (13). Treatment selection depends on multiple factors, such as the patient's risk profile, the surgical procedure, and current medical conditions. Combination therapy involving medications from different classes is frequently employed to manage PONV effectively.



### Antiemetics

A variety of antiemetics employ diverse mechanisms to prevent and alleviate PONV. Studies indicate that antiemetics can decrease the risk of PONV by 25% (28). Tailored to each patient, healthcare providers select antiemetics based on individual patient risk factors and any potential side effects. Higher-risk patients who receive antiemetics generally experience more excellent symptom relief than lower-risk patients (28). However, all antiemetics carry potential side effects. If an antiemetic was administered prophylactically, rescue treatment should involve an antiemetic from a different drug class (45).

### Serotonin receptor antagonists

The 5-HT<sub>3</sub> receptor antagonists selectively block serotonin 5-HT<sub>3</sub> receptors, including first-generation serotonin antagonists such as ondansetron, granisetron, and dolasetron, which are commonly used for both the prevention and treatment of PONV (46). Ondansetron, a 5-HT<sub>3</sub> receptor antagonist, blocks serotonin receptors in the gastrointestinal tract, CTZ, and NTS (47). In adults, ondansetron is typically administered at a dose of 4 mg intravenously or 8 mg orally before surgery (4, 28, 48, 49, 50). In children, the dose is 0.1 mg/kg intravenously, with a maximum dose of 4 mg (51). Ondansetron may cause well-tolerated side effects, such as headaches, constipation, serotonin syndrome, and flushing (47). On rare occasions, ondansetron may result in prolonged QT syndrome (47).

For granisetron, the recommended dose for adults is 1 mg intravenously (52), and for children, it is 40 mcg/kg intravenously, with a maximum dose of 0.6 mg (53). Common side effects from granisetron include headaches (10-15% incidence), constipation, somnolence, diarrhea, and minor transient changes in blood pressure (54). Dolasetron is typically administered at a dose of 12.5 mg intravenously in adults (4,55), and in children, the dose is 0.35 mg/kg intravenously, with

a maximum dose of 12.5 mg. Common side effects of dolasetron include headaches, dizziness, and diarrhea (56). Antiemetics can prolong the QT interval and should be avoided in at-risk patients (4).

Second-generation serotonin antagonist, palonosetron, is administered intravenously at a dose of 0.075 mg in adults and 0.5 to 1.5 mcg/kg in children at the induction of anesthesia (57). Palonosetron exhibits higher receptor binding affinity and has a longer half-life of 40 hours without affecting the QT interval. (58,59). Common side effects of palonosetron include headaches and dizziness. Palonosetron is particularly effective in preventing early PONV and vomiting after laparoscopic surgery (60).

### Glucocorticoids

Dexamethasone is commonly used for the reduction of PONV. Dexamethasone is known to have a slow onset but is more effective when administered after induction. In adults, dexamethasone is typically administered at a dose of 4 mg intravenously after induction (61), while in children, the dose is 0.25 mg/kg with a maximum of 4 mg (62). Dexamethasone, a corticosteroid, exerts its antiemetic effects through its anti-inflammatory properties (9,63). Dexamethasone is often used as an adjunct to other antiemetics for prophylaxis and is typically administered intravenously at the induction of anesthesia. Side effects of dexamethasone may include hyperglycemia, perineal pain with rapid IV bolus administration, and mental disturbances (64).

According to a recent analysis of 38 studies, dexamethasone is not likely to increase the risk of postoperative infection. However, due to imprecise trial results, its effect on delayed wound healing still needs to be determined (65). Dexamethasone may cause a mild increase in glucose levels, especially in patients without diabetes, with limited evidence suggesting a more pronounced increase in diabetic patients (65).

### Anticholinergics

Scopolamine, an anticholinergic medication, is commonly applied as a 1.5 mg transdermal patch for PONV prophylaxis. This long-acting patch should be applied at least 2 hours before anesthesia (66, 2). Side effects are generally mild and may include dry mouth and blurry vision (4,66, 67). However, in older adults, confusion or agitation may occur (41, 68), and acute angle-closure glaucoma is a potential side effect (44). Therefore, it is contraindicated in patients with angle-closure glaucoma (69).

### Antidopaminergics

Dopamine receptor antagonists like Droperidol block dopamine receptors in the CTZ (9). Droperidol is typically administered at a dose of 0.625-1.25 mg intravenously. At the same time, haloperidol is given at a dose of 1 mg intravenously, orally, or intramuscularly, and amisulpride at a dose of 5 mg intravenously at the induction of anesthesia (4, 70). Haloperidol and droperidol are given as single IV doses at the end of surgery, with haloperidol having the option of oral or intramuscular administration. However, haloperidol and droperidol are not used for PONV prophylaxis in children. Droperidol, used for treatment, can cause sedation, prolonged QT, and lactation.

Additionally, since droperidol does not readily cross the BBB, it is thus suitable for patients with Parkinson's disease due to droperidol's reduced risk of extrapyramidal symptoms. Patients receiving droperidol should be monitored with ECG for arrhythmias (71). Amisulpride is a newer drug associated with a mild elevation in serum prolactin, hypokalemia, chills, hypotension during injection, and pain at the injection site (72). Amisulpride should be avoided in patients with congenital long QT syndrome.

### Neurokinin 1 receptor antagonists

Long-acting antiemetics such as fosaprepitant and oral/IV aprepitant have a half-life of 40 hours (73). Aprepitant blocks substance P, a neurotransmitter involved in the vomiting reflex, and is frequently used in combination with a 5-HT<sub>3</sub> antagonist like ondansetron to enhance the prevention of PONV (4,6,9). In adults, oral aprepitant is administered at a dose of 40 mg preoperatively (74, 75), while fosaprepitant is given at a dose of 150 mg IV preoperatively (76).

### Antihistamines

Antihistamines such as cyclizine, diphenhydramine, and dimenhydrinate function by blocking histamine receptors, offering antiemetic effects for preventing and treating PONV (10). When administered at a dose of 50 mg orally or intravenously, cyclizine, which also exhibits some anticholinergic activity, may lead to antimuscarinic effects such as tachycardia, dry eyes, dry mouth, blurred vision, and sedation (13).

Diphenhydramine can be administered via intramuscular, oral, or rectal routes. The recommended dose for diphenhydramine is 1 mg/kg intravenously in adults and 0.5 mg/kg with a maximum of 25 mg in children (77). Common side effects include sedation, dry mouth, dizziness, and urinary retention (78).

### Phenothiazines

Promethazine is administered intravenously at a dose ranging from 6.25 to 12.5 mg at the induction of anesthesia (79, 80, 81). It acts like an anticholinergic and antihistamine. Side effects include sedation, delirium, confusion, vision changes, seizures, fast or difficulty breathing, and fast or irregular pulse (4, 82).

### Sedatives

When administered at the doses required for Total Intravenous Anesthesia (TIVA), certain sedatives like Propofol possess antiemetic properties (83, 84). For patients under 55 years old with

mild systemic disease, an initial intravenous dose of 40 mg should be administered every 10 seconds until the onset of action is achieved. However, if patients are not premedicated with oral benzodiazepines or intramuscular opioids, the initial dose should be adjusted to 2-2.5 mg/kg intravenously. For patients over 55 years old, debilitated, or with a severe systemic disease that is not life-threatening, a lower initial intravenous dose of 20 mg should be given every 10 seconds until the onset of action is reached. Rapid bolus administration should be avoided to reduce the risk of adverse cardiorespiratory effects such as hypotension, apnea, airway obstruction, and oxygen desaturation.

In a 2015 double-blinded study, patients were randomized into four groups and received either Propofol 20 mg, Propofol 30 mg, Metoclopramide 10 mg, or a placebo (85). The prevalence of PONV within 0-6 hours after anesthesia was significantly lower in the Propofol groups compared to the placebo group (85). The study indicated that a subhypnotic dose of Propofol (30 mg) was as effective as Metoclopramide (10 mg) in reducing the incidence and severity of PONV in the study patients (85).

### Combination therapy


To achieve PONV prophylaxis, combining at least two antiemetics from different drug classes (73, 86). This combination approach is more effective in preventing PONV in children and adults (4, 87).

### **Non-pharmacological Treatment**

Non-pharmacological treatments include a variety of interventions that do not involve medication. Non-pharmacological treatments can be used alone or alongside pharmacological treatments.

## Acupressure

One such intervention is acupressure, which involves applying pressure to specific acupuncture points on the body (28). As illustrated in Figure 1 below, stimulating the P6 point, located three finger-widths away from the inner wrist, has been found to help alleviate motion sickness (28, 88). In a 2015 review, 40 trials were analyzed, showing that the stimulation of the P6 acupoint effectively reduced PONV, with only minor side effects. This intervention was considered comparable to the efficacy and safety of antiemetic drugs (69). Another study assessed the impact of acupressure on PONV in laparoscopic surgery. Analyzing 11 randomized controlled trials involving 941 patients, acupressure significantly decreased the incidence of nausea, vomiting, and the need for antiemetic drugs in the early and extended postoperative phases (70). The findings suggest that acupressure is an effective non-pharmacological intervention for managing PONV in laparoscopic procedures (70).



*Figure 1*  
*Illustration of the P6 Point (88)*

### Acupuncture

Acupuncture involves the insertion of thin needles into specific points on the body to achieve therapeutic effects (46, 50). A 2021 meta-analysis examined the effectiveness and safety of acupuncture therapy for PONV following gynecologic surgery. The 2021 meta-analysis included nine randomized controlled trials and one prospective cohort study covering 1,075 participants (72). Results showed that acupuncture therapy significantly reduced the risk of PONV by 48% and 42% for nausea and vomiting, respectively (72). There were no significant differences in side effects between groups, and acupuncture therapy was associated with lower rescue antiemetic usage and higher postoperative recovery satisfaction. The study suggests that acupuncture is an effective and safe therapy for preventing PONV in gynecologic surgery patients (72).

### Ginger

Ginger, known for its natural antiemetic properties, can be consumed in different forms, including ginger tea or capsules (48,49). In a 2021 study, the authors aimed to assess the preventive efficacy of ginger on PONV through a systematic review and meta-analysis. Fourteen studies involving 1417 participants were included. Compared to placebo, the ginger group showed significantly lower nausea severity, reduced rescue antiemetic use, and lower incidence of nausea and vomiting over 6 hours post-operation (75). Compared to prophylactic antiemetics, ginger significantly reduced the incidence of nausea but showed no significant difference in vomiting or rescue antiemetic use. The findings suggest ginger could be an effective alternative for preventing PONV, although more research is needed to compare its efficacy with traditional antiemetics (75).

### Hydration

Proper hydration before and after surgery has been shown to help alleviate PONV symptoms and adhere to dietary modifications. Patients should adhere to fasting guidelines before surgery and include light, easily digestible meals after surgery (28). In a 2007 study, the authors investigated the impact of preoperative and intraoperative hydration on PONV in patients undergoing laparoscopic cholecystectomy. In the study, 210 patients were randomly assigned to receive either preoperative or intraoperative volume replacement. Results showed a significant reduction in PONV in the preoperative replacement group compared to the intraoperative group. The study results suggest that replacing fluid deficits preoperatively can effectively reduce PONV (74).

### Aromatherapy

Deep breathing and relaxation techniques, including aromatherapy, have been demonstrated to reduce stress and anxiety and alleviate nausea (51). In a 2018 systematic review, the authors assessed the impact of aromatherapy on PONV in adult surgical patients. The review included five randomized controlled trials and found that aromatherapy positively affected reducing PONV. Therefore, the author's findings suggest aromatherapy could be considered as a complementary therapy or adjunct to antiemetic medications for managing PONV. However, more research is needed to support the use of aromatherapy in this context further, and future studies could focus on standardizing nausea assessment scales to improve the reliability and validity of research findings on PONV (76).

### **Complications**

Postoperative nausea and vomiting can lead to various complications that significantly impact the patient's overall well-being and recovery process (11,20). Complications due to PONV



have the potential to prolong the patient's recovery period after surgery, causing significant discomfort and distress for the patient during the postoperative period.

### Dehydration

Continuous vomiting can result in fluid loss, potentially leading to dehydration (89).

### Electrolyte Disturbances

Vomiting can disrupt patients' electrolyte levels, impacting vital bodily functions, including potassium and sodium (90). Sodium is critical in maintaining extracellular fluid volume and regulating cell membrane potential. Common electrolyte disorders associated with sodium include hyponatremia and hypernatremia (81). Potassium, primarily located intracellularly, contributes to maintaining cell membrane potential and is regulated through various mechanisms. Imbalances in potassium levels, such as hypokalemia and hyperkalemia, can potentially induce cardiac arrhythmias (81).

### Alkalosis

Prolonged vomiting may even lead to metabolic alkalosis, which involves the loss of hydrogen (acidic component) and chloride (91). Metabolic alkalosis is a common acid-base imbalance seen particularly in hospitalized patients, characterized by elevated serum bicarbonate and arterial pH, often accompanied by increased Pco<sub>2</sub> due to compensatory hypoventilation. It can result from acid loss or bicarbonate accumulation in the body, often through gastrointestinal or renal mechanisms (80).

### Aspiration

Severe vomiting poses an elevated risk of aspiration, where the stomach contents may enter the respiratory system, potentially leading to pneumonia and other respiratory complications (21).

### Wound Damage

Dehiscence is the partial or complete separation of previously approximated wound edges, typically manifesting 5 to 8 days after surgery. Factors contributing to this complication include ischemia, infection, elevated abdominal pressure, diabetes, malnutrition, smoking, and obesity (84). Excessive abdominal contractions during vomiting may exacerbate the risk of wound dehiscence in patients who have undergone abdominal surgery (22).

### **Prevention**

Prevention of PONV involves addressing various risk factors that contribute to its development. The prevention of PONV is critical due to its distressing nature for patients and the potential to delay recovery. Several preventative measures can help minimize the risk, including identifying high-risk patients based on factors such as history of PONV, motion sickness, gender, smoking status, and type of surgery, utilizing tools like the APFEL scoring system. (4,11,28,29,92) Prophylactic measures for PONV should be tailored to individual patient risk factors to reduce the incidence of PONV effectively.

The Society of Ambulatory Anesthesia (SAMBA) presents a straightforward risk evaluation method, incorporating point-based assessments for distinct risk factors and practical guidelines for managing at-risk patients. As seen below, Figure 2 lays out SAMBA's guidelines to reduce the risk of PONV.

1. Identify patients at risk for PONV.
2. Employ management strategies to reduce PONV risk.
3. Employ one to two prophylactic measures in adults at moderate PONV risk.
4. Use multiple interventions in patients at high PONV risk.
5. Administer prophylactic antiemetic therapy to children at high risk using combination therapy.
6. Provide antiemetic therapy to patients with PONV who did not receive prophylactic therapy or in whom prophylaxis failed. Therapy should be with a drug from a different class than that which failed to provide prophylaxis.

*Figure 2*  
*SAMBA Guidelines to Reduce the Risk of PONV (4,92)*

*Prevention in Adults*

PONV prophylaxis is recommended for adults, with standard prophylaxis consisting of two antiemetics, such as dexamethasone with a 5-HT3 receptor antagonist. (Figure 2) High-risk patients may require additional antiemetics with different mechanisms of action. (Figure 2) Combination therapy is generally more effective than single agents (83). Additionally, they are educating patients about the importance of promptly reporting any symptoms of nausea or vomiting to healthcare providers (11).

### Antiemetics in adults

Administering antiemetic medications before surgery to high-risk patients has been shown to help prevent PONV (11,12). Commonly used options include 5-HT<sub>3</sub> antagonists, D<sub>2</sub> receptor antagonists, and corticosteroids.

In adult patients without preoperative risk factors but are undergoing inhalation anesthesia or total intravenous anesthesia (TIVA) with opioids, standard practice typically involves administering dexamethasone 4 to 8 mg intravenously after anesthesia induction and ondansetron 4 mg after surgery (93). A study indicated that the combination of ondansetron and dexamethasone resulted in lower nausea scores at 0, 2, and 24 hours postoperatively compared to ondansetron alone (73). Additionally, vomiting was significantly lower in the combination group than the ondansetron-alone group (73).

A multimodal approach to antiemetic administration is recommended. Just 2 hours prior to anesthesia induction, patients can apply a scopolamine patch, which should be removed 24 hours after surgery. Following anesthesia induction, intravenous dexamethasone (4-8 mg) is typically administered. After surgery, intravenous ondansetron (4 mg) is commonly given. In the event of PONV occurrence in the post-anesthesia care unit, an antiemetic from a different class may be warranted. Options include intravenous prochlorperazine (5-10 mg) or droperidol (0.625 mg) (23).

### Prevention in Children

PONV prophylaxis is recommended for children, with standard prophylaxis consisting of two antiemetics, such as dexamethasone with a 5-HT<sub>3</sub> receptor antagonist. (Figure 2) For high-risk children with more than three risk factors, regional anesthesia with sedation is preferred for older children (94). If the surgery requires general anesthesia, then total intravenous anesthesia (TIVA) with Propofol is used for high-risk patients (94). Children with one or two risk factors are

managed similarly to high-risk patients, except not using TIVA. The choice for children without risk factors is based on doctor and patient preference.

### Antiemetics in children

Dexamethasone is given at 0.25 mg/kg intravenously, while ondansetron is administered at 0.1 mg/kg intravenously (62,95). In cases where rescue antiemetics are needed, dimenhydrinate or diphenhydramine can be administered intravenously at a dosage of 0.5 mg/kg, with a maximum of 25 mg (62,95). If a repeat dose of ondansetron is required, it should be given intravenously at 0.1 mg/kg, with a maximum dose of 4 mg (62,95).

### Avoidance of Volatile anesthetics

Modifiable risk factors can also be addressed to effectively reduce the risk of postoperative complications. These include abstaining from the use of nitrous oxide, which has been linked to heightened risks, and opting for regional or local anesthesia over volatile agents whenever suitable for the patient (30).

### Minimizing Opioids

Minimizing opioid usage has also been shown to yield benefits. Recent studies suggested that opioid-free anesthesia may reduce the incidence and severity of PONV as well as decrease opioid consumption after surgery (63,96,97). If not contraindicated, patients can be administered nonsteroidal anti-inflammatory drugs and acetaminophen for pain relief.

### Hydration

Adequate hydration is crucial for preventing dehydration and optimizing postoperative pain management (25,28). Studies have demonstrated that administering intravenous (IV)

crystalloid solutions in adults reduces the risk of PONV (67). In pediatric patients, IV fluid administration has been linked to decreased PONV (68).

A study focused on preoperative IV fluid supplementation, comparing crystalloids and colloids in female patients undergoing elective open cholecystectomy. The study, involving 60 participants, randomized the participants into three groups: 1 control group receiving Ringer lactate IV and two experimental groups receiving varying volumes of Ringer lactate or hydroxyethyl starch. (77). The results indicated that both crystalloids and colloids significantly reduced the incidence of PONV compared to the control group, with no significant difference observed between the two fluid types (77).

### **Future Directions**

The future of PONV entails advancements in comprehending its underlying mechanisms and devising more efficient prevention and management strategies. As research advances in these domains, the goal is to enhance existing approaches and elevate the overall quality of care and patient experience during and after surgical procedures.

### Genetics

Ongoing research explores the genetic factors that influence an individual's susceptibility to PONV. At the University of Miami, a study was conducted to explore the role of genetics in the management of PONV (52). The authors discussed various genetic polymorphisms related to serotonin, dopamine, and muscarinic receptors, as well as the involvement of pharmacogenomics in the pathophysiology of PONV. The authors highlighted the potential for personalized medicine in the future, where genetic testing could help identify individual patient risks and responses (52).

Investigations into metabolic pathways, including CYP450 2D6 isoform (CYP2D6), have also been conducted due to their involvement in metabolizing antiemetics (98).

In a separate study, the researchers focused on identifying patients at risk of PONV by characterizing genetic risk factors. The researchers genotyped 601 patients who were followed for PONV symptoms during the first 24 hours after surgery without antiemetic prophylaxis (99). The authors examined the impact of selected single nucleotide polymorphisms around 13 different genes and the predicted activity of 6 liver drug-metabolizing enzymes from the cytochrome P450 family on the occurrence and recurrence of PONV (99). The study confirmed the significance of genetic variations in the type 3B serotonin receptor in the occurrence of PONV and suggested that integrating the rs3782025 genotype into preoperative risk assessments may improve the targeting of antiemetic prophylaxis for patients at risk of PONV (99).

### *Nerve Stimulation*

Advancements in non-invasive neurostimulation methods, such as transcutaneous electrical nerve stimulation, promise to mitigate PONV by modulating neural pathways (55, 57). In a study from 2000, the authors explored the efficacy of transcutaneous impulse stimulation in averting PONV following gynecological surgery. Seventy women undergoing elective procedures were randomly assigned to an activated (stimulation group) or inactive (non-stimulation group) impulse stimulation. The stimulator, placed over the mastoid processes and nuchal region, delivered adjustable electrical pulses. Results indicated reduced postoperative nausea scores, diminished vomiting incidence, and decreased postoperative dizziness in the stimulation group. Moreover, less antiemetic medication was needed in the stimulation group compared to the non-

stimulation group. The findings suggest that electrical vestibular system stimulation may hold promise in PONV prevention (100).

## **Conclusion**

PONV is a multifactorial challenge that impacts a significant portion of patients undergoing anesthesia and surgery. Understanding the various contributing factors, including patient characteristics, anesthetic techniques, and surgical procedures, is essential for effective PONV prevention and management. Patient-specific factors, such as gender, age, smoking status, and history of PONV or motion sickness, along with preoperative anxiety, play significant roles in determining an individual's PONV risk. Anesthetic factors like the choice of anesthesia and specific drugs used can also influence the likelihood of PONV, with regional anesthesia and certain medications like Propofol associated with lower rates.

The regulation of vomiting involves complex neural pathways and neurotransmitter systems, offering potential targets for pharmacological interventions. Antiemetic medications targeting serotonin, dopamine, histamine, and other receptors are commonly used to enhance efficacy. Non-pharmacological interventions such as acupressure, acupuncture, ginger supplementation, hydration, and aromatherapy provide alternative approaches to managing PONV. Non-pharmacological interventions can also complement pharmacotherapy.

Complications of PONV, including dehydration, electrolyte disturbances, aspiration, and wound complications, underscore the importance of prevention. Identifying high-risk patients, employing prophylactic measures such as combination therapy, and addressing modifiable risk factors are critical strategies in PONV prevention. The future of PONV management holds promise



with ongoing research into genetic factors, nerve stimulation techniques, and refined risk stratification models.

## Acknowledgments

First, I thank Dr. Vilena Vrbanović Mijatović from the Department of Anesthesiology, Reanimatology, and Intensive Care at the University Hospital Centre Zagreb. I would not have been able to complete this thesis without the invaluable support of my mentor, Dr. Vilena Vrbanović Mijatović. Dr. Vilena Vrbanović Mijatović played a vital role in developing my thesis by providing guidance, corrections, insightful comments, and feedback. I would also like to thank the University of Zagreb School of Medicine's Final Exams Committee for evaluating this graduate thesis. Finally, I would like to thank my parents and brother for their years of unwavering support and encouragement. This achievement would not have been possible without them.

## References

1. Choi SU. Is postoperative nausea and vomiting still the big "little" problem? *Korean J Anesthesiol.* 2016 Feb;69(1):1-2. doi: 10.4097/kjae.2016.69.1.1. Epub 2016 Jan 28. PMID: 26885293; PMCID: PMC4754258.
2. Gan TJ, Belani KG, Bergese S, Chung F, Diemunsch P, Habib AS, Jin Z, Kovac AL, Meyer TA, Urman RD, Apfel CC, Ayad S, Beagley L, Candiotti K, Englesakis M, Hedrick TL, Kranke P, Lee S, Lipman D, Minkowitz HS, Morton J, Philip BK. Fourth Consensus Guidelines for the Management of Postoperative Nausea and Vomiting. *Anesth Analg.* 2020 Aug;131(2):411-448. doi: 10.1213/ANE.0000000000004833. Erratum in: *Anesth Analg.* 2020 Nov;131(5):e241. PMID: 32467512.
3. Le TP, Gan TJ. Update on the management of postoperative nausea and vomiting and postdischarge nausea and vomiting in ambulatory surgery. *Anesthesiol Clin.* 2010 Jun;28(2):225-49. doi: 10.1016/j.anclin.2010.02.003. PMID: 20488392.
4. Butterworth JF, Mackey DC, Wasnick JD. *Morgan and Mikhail's clinical anesthesiology.* 5th ed. New York, NY: McGraw-Hill Medical; 2013. 283–287 p.
5. Stoops S, Kovac A. New insights into the pathophysiology and risk factors for PONV. *Best Pract Res Clin Anaesthesiol.* 2020 Dec;34(4):667-679. doi: 10.1016/j.bpa.2020.06.001. Epub 2020 Jun 10. PMID: 33288117.
6. Elsaid RM, Namrouti AS, Samara AM, Sadaqa W, Zyoud SH. Assessment of pain and postoperative nausea and vomiting and their association in the early postoperative period: an observational study from Palestine. *BMC Surg.* 2021 Apr 1;21(1):177. doi: 10.1186/s12893-021-01172-9. PMID: 33794852; PMCID: PMC8017875.
7. Brampton W, Dryburgh IR, Wynn-Hebden A, Kumar A. Simplified measures of postoperative nausea and vomiting do not transfer to other populations. *Br J Anaesth.* 2013 Oct;111(4):677-8. doi: 10.1093/bja/aet319. PMID: 24027150.

8. Thompson HJ. The management of post-operative nausea and vomiting. *J Adv Nurs*. 1999 May;29(5):1130-6. doi: 10.1046/j.1365-2648.1999.00998.x. PMID: 10320496.
9. Horn CC, Wallisch WJ, Homanics GE, Williams JP. Pathophysiological and neurochemical mechanisms of postoperative nausea and vomiting. *Eur J Pharmacol*. 2014 Jan 5;722:55-66. doi: 10.1016/j.ejphar.2013.10.037. Epub 2013 Oct 26. PMID: 24495419; PMCID: PMC3915298.
10. Shaikh SI, Nagarekha D, Hegade G, Marutheesh M. Postoperative nausea and vomiting: A simple yet complex problem. *Anesth Essays Res*. 2016 Sep-Dec;10(3):388-396. doi: 10.4103/0259-1162.179310. PMID: 27746521; PMCID: PMC5062207.
11. Urits I, Orhurhu V, Jones MR, Adamian L, Borchart M, Galasso A, Viswanath O. Postoperative Nausea and Vomiting in Paediatric Anaesthesia. *Turk J Anaesthesiol Reanim*. 2020 Apr;48(2):88-95. doi: 10.5152/TJAR.2019.67503. Epub 2019 Nov 11. PMID: 32259138; PMCID: PMC7101192.
12. Apfel CC, Heidrich FM, Jukar-Rao S, Jalota L, Hornuss C, Whelan RP, Zhang K, Cakmakkaya OS. Evidence-based analysis of risk factors for postoperative nausea and vomiting. *Br J Anaesth*. 2012 Nov;109(5):742-53. doi: 10.1093/bja/aes276. Epub 2012 Oct 3. PMID: 23035051.
13. Elvir-Lazo OL, White PF, Yumul R, Cruz Eng H. Management strategies for the treatment and prevention of postoperative/postdischarge nausea and vomiting: an updated review. *F1000Res*. 2020 Aug 13;9:F1000 Faculty Rev-983. doi: 10.12688/f1000research.21832.1. PMID: 32913634; PMCID: PMC7429924.
14. Morrison C, Wilmshurst S. Postoperative vomiting in children. *BJA Educ*. 2019 Oct;19(10):329-333. doi: 10.1016/j.bjae.2019.05.006. Epub 2019 Aug 22. PMID: 33456854; PMCID: PMC7808069.

15. Cohen MM, Duncan PG, DeBoer DP, Tweed WA. The postoperative interview: assessing risk factors for nausea and vomiting. *Anesth Analg*. 1994 Jan;78(1):7-16. doi: 10.1213/00000539-199401000-00004. PMID: 8267183.
16. Alassaf HM, Sobahi AM, Alshahrani NS. The efficacy and safety of dexmedetomidine in preventing emergence delirium in paediatric patients following ophthalmic surgery: a systematic review and meta-analysis of randomised controlled trials. *J Anesth Analg Crit Care*. 2022 Dec 12;2(1):48. doi: 10.1186/s44158-022-00079-y. PMID: 37386601; PMCID: PMC9744040.
17. Kovac AL. Postoperative Nausea and Vomiting in Pediatric Patients. *Paediatr Drugs*. 2021 Jan;23(1):11-37. doi: 10.1007/s40272-020-00424-0. Epub 2020 Oct 27. PMID: 33108649.
18. Swaika S, Pal A, Chatterjee S, Saha D, Dawar N. Ondansetron, ramosetron, or palonosetron: Which is a better choice of antiemetic to prevent postoperative nausea and vomiting in patients undergoing laparoscopic cholecystectomy? *Anesth Essays Res*. 2011 Jul-Dec;5(2):182-6. doi: 10.4103/0259-1162.94761. PMID: 25885385; PMCID: PMC4173412.
19. Koivuranta M, Läärä E, Snåre L, Alahuhta S. A survey of postoperative nausea and vomiting. *Anaesthesia*. 1997 May;52(5):443-9. doi: 10.1111/j.1365-2044.1997.117-az0113.x. PMID: 9165963.
20. Apfel CC, Kranke P, Katz MH, Goepfert C, Papenfuss T, Rauch S, Heineck R, Greim CA, Roewer N. Volatile anaesthetics may be the main cause of early but not delayed postoperative vomiting: a randomized controlled trial of factorial design. *Br J Anaesth*. 2002 May;88(5):659-68. doi: 10.1093/bja/88.5.659. PMID: 12067003.
21. Sneyd JR, Carr A, Byrom WD, Bilski AJ. A meta-analysis of nausea and vomiting following maintenance of anaesthesia with propofol or inhalational agents. *Eur J Anaesthesiol*. 1998 Jul;15(4):433-45. doi: 10.1046/j.1365-2346.1998.00319.x. PMID: 9699101.

22. Tramèr M, Moore A, McQuay H. Omitting nitrous oxide in general anaesthesia: meta-analysis of intraoperative awareness and postoperative emesis in randomized controlled trials. *Br J Anaesth*. 1996 Feb;76(2):186-93. doi: 10.1093/bja/76.2.186. PMID: 8777095.
23. Chatterjee S, Rudra A, Sengupta S. Current concepts in the management of postoperative nausea and vomiting. *Anesthesiol Res Pract*. 2011;2011:748031. doi: 10.1155/2011/748031. Epub 2011 Nov 3. PMID: 22110499; PMCID: PMC3216269.
24. Sinclair DR, Chung F, Mezei G. Can postoperative nausea and vomiting be predicted? *Anesthesiology*. 1999 Jul;91(1):109-18. doi: 10.1097/00000542-199907000-00018. PMID: 10422935.
25. Weilbach C, Rahe-meyer N, Raymondos K, Weissig A, Scheinichen D, Piepenbrock S. Postoperative nausea and vomiting (PONV) : usefulness of the Apfel-score for identification of high risk patients for PONV. *Acta Anaesthesiol Belg*. 2006;57(4):361-3. PMID: 17236637.
26. van den Bosch JE, Kalkman CJ, Vergouwe Y, Van Klei WA, Bonsel GJ, Grobbee DE, Moons KG. Assessing the applicability of scoring systems for predicting postoperative nausea and vomiting. *Anaesthesia*. 2005 Apr;60(4):323-31. doi: 10.1111/j.1365-2044.2005.04121.x. PMID: 15766334.
27. Thomas R, Jones NA, Strike P. The value of risks scores for predicting postoperative nausea and vomiting when used to compare patient group in a randomised controlled trial. *Anaesthesia*. 2002 Nov;57(11):1119-28. doi: 10.1046/j.1365-2044.2002.02782\_4.x. PMID: 12428640.
28. Apfel CC, Korttila K, Abdalla M, Kerger H, Turan A, Vedder I, Zernak C, Danner K, Jokela R, Pocock SJ, Trenkler S, Kredel M, Biedler A, Sessler DI, Roewer N; IMPACT Investigators. A factorial trial of six interventions for the prevention of postoperative nausea and vomiting. *N Engl J Med*. 2004 Jun 10;350(24):2441-51. doi: 10.1056/NEJMoa032196. PMID: 15190136; PMCID: PMC1307533.

29. Sherif L, Hegde R, Mariswami M, Ollapally A. Validation of the Apfel scoring system for identification of high-risk patients for PONV. *Karnataka Anaesth J.* 2015 Jan;1(3):115. doi:10.4103/2394-6954.173527
30. Darvall J, Handscombe M, Maat B, So K, Suganthirakumar A, Leslie K. Interpretation of the four risk factors for postoperative nausea and vomiting in the Apfel simplified risk score: an analysis of published studies. *Can J Anaesth.* 2021 Jul;68(7):1057-1063. English. doi: 10.1007/s12630-021-01974-8. Epub 2021 Mar 15. PMID: 33721198.
31. Öbrink E, Jildenstål P, Oddby E, Jakobsson JG. Post-operative nausea and vomiting: update on predicting the probability and ways to minimize its occurrence, with focus on ambulatory surgery. *Int J Surg.* 2015 Mar;15:100-6. doi: 10.1016/j.ijso.2015.01.024. Epub 2015 Jan 29. PMID: 25638733.
32. Avinash SH, Krishna HM. The impact of the Apfel scoring system for prophylaxis of postoperative nausea and vomiting: A randomized controlled trial. *J Anaesthesiol Clin Pharmacol.* 2023 Jul-Sep;39(3):463-467. doi: 10.4103/joacp.joacp\_553\_21. Epub 2023 Jun 2. PMID: 38025550; PMCID: PMC10661641.
33. Apfel CC, Läärä E, Koivuranta M, Greim CA, Roewer N. A simplified risk score for predicting postoperative nausea and vomiting: conclusions from cross-validations between two centers. *Anesthesiology.* 1999 Sep;91(3):693-700. doi: 10.1097/00000542-199909000-00022. PMID: 10485781.
34. Sommerfield D, Sommerfield A, Evans D, Khan RN, Luke A, Vijayasekaran S, Bumbak P, Herbert H, von Ungern-Sternberg BS. Jelly snakes to reduce early postoperative vomiting in children after adenotonsillectomy: The randomized controlled snakes trial. *Anaesth Crit Care Pain Med.* 2024 Feb;43(1):101334. doi: 10.1016/j.accpm.2023.101334. Epub 2023 Dec 2. PMID: 38048987.

35. Eberhart LHJ, Geldner G, Kranke P, Morin AM, Schäuffelen A, Treiber H, Wulf H. The development and validation of a risk score to predict the probability of postoperative vomiting in Pediatric patients. *Anesth Analg.* 2004 Dec;99(6):1630-1637. doi: 10.1213/01.ANE.0000135639.57715.6C. PMID: 15562045.
36. Cao X, White PF, Ma H. An update on the management of postoperative nausea and vomiting. *J Anesth.* 2017 Aug;31(4):617-626. doi: 10.1007/s00540-017-2363-x. Epub 2017 Apr 28. PMID: 28455599.
37. Miller AD, Leslie RA. The area postrema and vomiting. *Front Neuroendocrinol.* 1994 Dec;15(4):301-20. doi: 10.1006/frne.1994.1012. PMID: 7895890.
38. Cangemi DJ, Kuo B. Practical Perspectives in the Treatment of Nausea and Vomiting. *J Clin Gastroenterol.* 2019 Mar;53(3):170-178. doi: 10.1097/MCG.0000000000001164. PMID: 30614944.
39. Jawabri KH, Sharma S. Physiology, Cerebral Cortex Functions. 2023 Apr 24. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. PMID: 30860731.
40. Zhong W, Shahbaz O, Teskey G, Beever A, Kachour N, Venketaraman V, Darmani NA. Mechanisms of Nausea and Vomiting: Current Knowledge and Recent Advances in Intracellular Emetic Signaling Systems. *Int J Mol Sci.* 2021 May 28;22(11):5797. doi: 10.3390/ijms22115797. PMID: 34071460; PMCID: PMC8198651.
41. Lepot A, Elia N, Tramèr MR, Rehberg B. Preventing pain after breast surgery: A systematic review with meta-analyses and trial-sequential analyses. *Eur J Pain.* 2021 Jan;25(1):5-22. doi: 10.1002/ejp.1648. Epub 2020 Oct 4. PMID: 32816362.
42. Jolley S. Managing post-operative nausea and vomiting. *Nurs Stand.* 2001 Jun 20-26;15(40):47-52; quiz 53-5. doi: 10.7748/ns2001.06.15.40.47.c3044. PMID: 12206076.



43. Mawe GM, Hoffman JM. Serotonin signalling in the gut--functions, dysfunctions and therapeutic targets. *Nat Rev Gastroenterol Hepatol*. 2013 Aug;10(8):473-86. doi: 10.1038/nrgastro.2013.105. Epub 2013 Jun 25. Erratum in: *Nat Rev Gastroenterol Hepatol*. 2013 Oct;10(10):564. PMID: 23797870; PMCID: PMC4048923.
44. Li N, Liu L, Sun M, Wang R, Jin W, Liu C, Hu Y. Predominant role of gut-vagus-brain neuronal pathway in postoperative nausea and vomiting: evidence from an observational cohort study. *BMC Anesthesiol*. 2021 Sep 29;21(1):234. doi: 10.1186/s12871-021-01449-9. PMID: 34587905; PMCID: PMC8480048.
45. Candiotti KA, Ahmed SR, Cox D, Gan TJ. Palonosetron versus ondansetron as rescue medication for postoperative nausea and vomiting: a randomized, multicenter, open-label study. *BMC Pharmacol Toxicol*. 2014 Aug 16;15:45. doi: 10.1186/2050-6511-15-45. PMID: 25127659; PMCID: PMC4152758.
46. Tramèr MR, Reynolds DJ, Moore RA, McQuay HJ. Efficacy, dose-response, and safety of ondansetron in prevention of postoperative nausea and vomiting: a quantitative systematic review of randomized placebo-controlled trials. *Anesthesiology*. 1997 Dec;87(6):1277-89. doi: 10.1097/00000542-199712000-00004. PMID: 9416710.
47. López-Morales P, Flores-Funes D, Sánchez-Migallón EG, Lirón-Ruiz RJ, Aguayo-Albasini JL. Genetic Factors Associated with Postoperative Nausea and Vomiting: a Systematic Review. *J Gastrointest Surg*. 2018 Sep;22(9):1645-1651. doi: 10.1007/s11605-018-3788-8. Epub 2018 May 3. PMID: 29725907.
48. Honkavaara P. Effect of ondansetron on nausea and vomiting after middle ear surgery during general anaesthesia. *Br J Anaesth*. 1996 Feb;76(2):316-8. doi: 10.1093/bja/76.2.316. PMID: 8777119.

49. Dershwitz M, Conant JA, Chang Y, Rosow CE, Connors PM. A randomized, double-blind, dose-response study of ondansetron in the prevention of postoperative nausea and vomiting. *J Clin Anesth.* 1998 Jun;10(4):314-20. doi: 10.1016/s0952-8180(98)00035-x. PMID: 9667348.
50. Zarate E, Watcha MF, White PF, Klein KW, Sa Rego M, Stewart DG. A comparison of the costs and efficacy of ondansetron versus dolasetron for antiemetic prophylaxis. *Anesth Analg.* 2000 Jun;90(6):1352-8. doi: 10.1097/00000539-200006000-00017. PMID: 10825320.
51. Khalil SN, Roth AG, Cohen IT, Simhi E, Ansermino JM, Bolos ME, Coté CJ, Hannallah RS, Davis PJ, Brooks PB, Russo MW, Anschuetz GC, Blackburn LM. A double-blind comparison of intravenous ondansetron and placebo for preventing postoperative emesis in 1- to 24-month-old pediatric patients after surgery under general anesthesia. *Anesth Analg.* 2005 Aug;101(2):356-361. doi: 10.1213/01.ANE.0000155261.27335.29. PMID: 16037143.
52. Dua N, Sethi N, Sood J, Jain P. Randomized double blind comparative study comparing efficacy of granisetron and ondansetron for the prophylactic control of postoperative nausea and vomiting in patients undergoing middle ear surgery. *Indian J Otolaryngol Head Neck Surg.* 2014 Jan;66(Suppl 1):252-6. doi: 10.1007/s12070-011-0464-7. Epub 2012 Jan 6. PMID: 24533393; PMCID: PMC3918338.
53. Cieslak GD, Watcha MF, Phillips MB, Pennant JH. The dose-response relation and cost-effectiveness of granisetron for the prophylaxis of pediatric postoperative emesis. *Anesthesiology.* 1996 Nov;85(5):1076-85. doi: 10.1097/00000542-199611000-00016. PMID: 8916825.
54. Plosker GL, Goa KL. Granisetron. A review of its pharmacological properties and therapeutic use as an antiemetic. *Drugs.* 1991 Nov;42(5):805-24. doi: 10.2165/00003495-199142050-00007. PMID: 1723376.
55. Philip BK, McLeskey CH, Chelly JE, McKenzie R, Kovac AL, Diemunsch P, DuBois DM. Pooled analysis of three large clinical trials to determine the optimal dose of dolasetron mesylate

needed to prevent postoperative nausea and vomiting. The Dolasetron Prophylaxis Study Group. *J Clin Anesth.* 2000 Feb;12(1):1-8. doi: 10.1016/s0952-8180(99)00123-3. PMID: 10773500.

56. Balfour JA, Goa KL. Dolasetron. A review of its pharmacology and therapeutic potential in the management of nausea and vomiting induced by chemotherapy, radiotherapy or surgery. *Drugs.* 1997 Aug;54(2):273-98. doi: 10.2165/00003495-199754020-00008. PMID: 9257083.

57. Kovac AL, Eberhart L, Kotarski J, Clerici G, Apfel C; Palonosetron 04-07 Study Group. A randomized, double-blind study to evaluate the efficacy and safety of three different doses of palonosetron versus placebo in preventing postoperative nausea and vomiting over a 72-hour period. *Anesth Analg.* 2008 Aug;107(2):439-44. doi: 10.1213/ane.0b013e31817abcd3. PMID: 18633021.

58. Rojas C, Stathis M, Thomas AG, Massuda EB, Alt J, Zhang J, Rubenstein E, Sebastiani S, Cantoreggi S, Snyder SH, Slusher B. Palonosetron exhibits unique molecular interactions with the 5-HT<sub>3</sub> receptor. *Anesth Analg.* 2008 Aug;107(2):469-78. doi: 10.1213/ane.0b013e318172fa74. Erratum in: *Anesth Analg.* 2008 Oct;107(4):1405. Massuda, Edward B [corrected to Massuda, Ed B]; Rubenstein, Ed [corrected to Rubenstein, Edward]. PMID: 18633025.

59. Rojas C, Thomas AG, Alt J, Stathis M, Zhang J, Rubenstein EB, Sebastiani S, Cantoreggi S, Slusher BS. Palonosetron triggers 5-HT<sub>3</sub> receptor internalization and causes prolonged inhibition of receptor function. *Eur J Pharmacol.* 2010 Jan 25;626(2-3):193-9. doi: 10.1016/j.ejphar.2009.10.002. Epub 2009 Oct 15. PMID: 19836386.

60. Chu R. Effect of Palonosetron on Physical Symptoms of Surgical Patients: A Systematic Review and Meta-Analysis. *Comput Math Methods Med.* 2022 Mar 27;2022:7474053. doi: 10.1155/2022/7474053. PMID: 35387223; PMCID: PMC8977333.

61. Gupta R, Srivastava S, Dhiraaj S, Chovatiya PP. Minimum Effective dose of Dexamethasone in Combination with Midazolam as Prophylaxis against Postoperative Nausea and Vomiting after

Laparoscopic Cholecystectomy. *Anesth Essays Res.* 2018 Apr-Jun;12(2):396-401. doi: 10.4103/aer.AER\_19\_18. PMID: 29962605; PMCID: PMC6020576.

62. Madan R, Bhatia A, Chakithandy S, Subramaniam R, Rammohan G, Deshpande S, Singh M, Kaul HL. Prophylactic dexamethasone for postoperative nausea and vomiting in pediatric strabismus surgery: a dose ranging and safety evaluation study. *Anesth Analg.* 2005 Jun;100(6):1622-1626. doi: 10.1213/01.ANE.0000150977.14607.E1. PMID: 15920184.

63. Wengritzky R, Mettho T, Myles PS, Burke J, Kakos A. Development and validation of a postoperative nausea and vomiting intensity scale. *Br J Anaesth.* 2010 Feb;104(2):158-66. doi: 10.1093/bja/aep370. Epub 2009 Dec 26. PMID: 20037151.

64. Nordin L, Nordlund A, Lindqvist A, Gislason H, Hedenbro JL. Corticosteroids or Not for Postoperative Nausea: A Double-Blinded Randomized Study. *J Gastrointest Surg.* 2016 Aug;20(8):1517-22. doi: 10.1007/s11605-016-3166-3. Epub 2016 May 23. PMID: 27216406.

65. Polderman JAW, Farhang-Razi V, van Dieren S, Kranke P, DeVries JH, Hollmann MW, Preckel B, Hermanides J. Adverse side-effects of dexamethasone in surgical patients - an abridged Cochrane systematic review. *Anaesthesia.* 2019 Jul;74(7):929-939. doi: 10.1111/anae.14610. Epub 2019 Mar 1. PMID: 30821852.

66. Gan TJ, Diemunsch P, Habib AS, Kovac A, Kranke P, Meyer TA, Watcha M, Chung F, Angus S, Apfel CC, Bergese SD, Candiotti KA, Chan MT, Davis PJ, Hooper VD, Lagoo-Deenadayalan S, Myles P, Nezat G, Philip BK, Tramèr MR; Society for Ambulatory Anesthesia. Consensus guidelines for the management of postoperative nausea and vomiting. *Anesth Analg.* 2014 Jan;118(1):85-113. doi: 10.1213/ANE.0000000000000002. Erratum in: *Anesth Analg.* 2014 Mar;118(3):689. Erratum in: *Anesth Analg.* 2015 Feb;120(2):494. PMID: 24356162.

67. Jewer JK, Wong MJ, Bird SJ, Habib AS, Parker R, George RB. Supplemental perioperative intravenous crystalloids for postoperative nausea and vomiting. *Cochrane Database Syst Rev.* 2019

Mar 29;3(3):CD012212. doi: 10.1002/14651858.CD012212.pub2. PMID: 30925195; PMCID: PMC6440702.

68. Puri S, Bandyopadhyay A, Ashok V. Supplemental intraoperative crystalloids for pediatric postoperative nausea and vomiting-A systematic review and meta-analysis. *Paediatr Anaesth*. 2023 Jan;33(1):38-45. doi: 10.1111/pan.14566. Epub 2022 Oct 8. PMID: 36178763.

69. Lee A, Fan LT. Stimulation of the wrist acupuncture point P6 for preventing postoperative nausea and vomiting. *Cochrane Database Syst Rev*. 2009 Apr 15;(2):CD003281. doi: 10.1002/14651858.CD003281.pub3. Update in: *Cochrane Database Syst Rev*. 2015;11:CD003281. PMID: 19370583; PMCID: PMC3113464.

70. Salamah HM, Elsayed E, Brakat AM, Abualkhair KA, Hussein MA, Saber SM, Abdelhaleem IA. The effects of acupressure on postoperative nausea and vomiting among patients undergoing laparoscopic surgery: A meta-analysis of randomized controlled trials. *Explore (NY)*. 2023 May-Jun;19(3):300-309. doi: 10.1016/j.explore.2022.10.015. Epub 2022 Oct 26. PMID: 36319586.

71. Yang J, Jiang Y, Chen Y, Sun M, Chen J, Zheng Q, Liang FR. Acupressure the PC6 point for alleviating postoperative nausea and vomiting: A systematic review protocol. *Medicine (Baltimore)*. 2019 Aug;98(33):e16857. doi: 10.1097/MD.00000000000016857. PMID: 31415419; PMCID: PMC6831167.

72. Zheng XZ, Xiong QJ, Liu D, Wei K, Lai Y. Effectiveness of Acupuncture Therapy on Postoperative Nausea and Vomiting After Gynecologic Surgery: A Meta-Analysis and Systematic Review. *J Perianesth Nurs*. 2021 Oct;36(5):564-572. doi: 10.1016/j.jopan.2020.12.005. Epub 2021 Aug 14. PMID: 34404603.

73. Rajeeva V, Bhardwaj N, Batra YK, Dhaliwal LK. Comparison of ondansetron with ondansetron and dexamethasone in prevention of PONV in diagnostic laparoscopy. *Can J Anaesth*. 1999 Jan;46(1):40-4. doi: 10.1007/BF03012512. PMID: 10078401.

74. Adanir T, Aksun M, Ozgürbüz U, Altin F, Sencan A. Does preoperative hydration affect postoperative nausea and vomiting? A randomized, controlled trial. *J Laparoendosc Adv Surg Tech A*. 2008 Feb;18(1):1-4. doi: 10.1089/lap.2007.0019. PMID: 18266566.
75. Zhu W, Dai Y, Huang M, Li J. Efficacy of Ginger in Preventing Postoperative Nausea and Vomiting: A Systematic Review and Meta-Analysis. *J Nurs Scholarsh*. 2021 Nov;53(6):671-679. doi: 10.1111/jnu.12691. Epub 2021 Jul 26. PMID: 34312974.
76. Asay K, Olson C, Donnelly J, Perlman E. The Use of Aromatherapy in Postoperative Nausea and Vomiting: A Systematic Review. *J Perianesth Nurs*. 2019 Jun;34(3):502-516. doi: 10.1016/j.jopan.2018.08.006. Epub 2018 Dec 29. PMID: 30600134.
77. Chaudhary S, Sethi AK, Motiani P, Adatia C. Pre-operative intravenous fluid therapy with crystalloids or colloids on post-operative nausea & vomiting. *Indian J Med Res*. 2008 Jun;127(6):577-81. PMID: 18765877.
78. Sicari V, Zabbo CP. Diphenhydramine. 2023 Jul 10. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. PMID: 30252266.
79. Kovac AL. Prevention and treatment of postoperative nausea and vomiting. *Drugs*. 2000 Feb;59(2):213-43. doi: 10.2165/00003495-200059020-00005. PMID: 10730546.
80. Do C, Vasquez PC, Soleimani M. Metabolic Alkalosis Pathogenesis, Diagnosis, and Treatment: Core Curriculum 2022. *Am J Kidney Dis*. 2022 Oct;80(4):536-551. doi: 10.1053/j.ajkd.2021.12.016. Epub 2022 May 5. PMID: 35525634.
81. Shrimanker I, Bhattarai S. Electrolytes. 2023 Jul 24. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. PMID: 31082167.

82. Diaz-Artiles A, Priesol AJ, Clark TK, Sherwood DP, Oman CM, Young LR, Karmali F. The Impact of Oral Promethazine on Human Whole-Body Motion Perceptual Thresholds. *J Assoc Res Otolaryngol*. 2017 Aug;18(4):581-590. doi: 10.1007/s10162-017-0622-z. Epub 2017 Apr 24. PMID: 28439720; PMCID: PMC5532182.
83. Kienbaum P, Schaefer MS, Weibel S, Schlesinger T, Meybohm P, Eberhart LH, Kranke P. Update PONV – Was gibt es Neues bei der Prophylaxe und Therapie von postoperativer Übelkeit und postoperativem Erbrechen? : Zusammenfassung rezenter Konsensusempfehlungen sowie Cochrane-Reviews zu Prophylaxe und Therapie postoperativer Übelkeit und postoperativen Erbrechens [Update on PONV-What is new in prophylaxis and treatment of postoperative nausea and vomiting? : Summary of recent consensus recommendations and Cochrane reviews on prophylaxis and treatment of postoperative nausea and vomiting]. *Anaesthesist*. 2022 Feb;71(2):123-128. German. doi: 10.1007/s00101-021-01045-z. Epub 2021 Oct 1. PMID: 34596699. treatment of postoperative nausea and vomiting]. *Der Anaesthesist* [Internet]. 2022 Feb 1 [cited 2023 May 17];71(2):123–8.
84. Rosen RD, Manna B. Wound Dehiscence. 2023 May 1. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan–. PMID: 31869176.
85. Naghibi K, Kashefi P, Azarnoush H, Zabihi P. Prevention of postoperative nausea and vomiting with a subhypnotic dose of Propofol in patients undergoing lower abdominal surgery: A prospective, randomized, double-blind study. *Adv Biomed Res*. 2015 Feb 11;4:35. doi: 10.4103/2277-9175.151239. PMID: 25789261; PMCID: PMC4358041.
86. Voigt M, Fröhlich CW, Waschke KF, Lenz C, Göbel U, Kerger H. Prophylaxis of postoperative nausea and vomiting in elective breast surgery. *J Clin Anesth*. 2011 Sep;23(6):461-8. doi: 10.1016/j.jclinane.2011.01.005. PMID: 21911192.
87. Viderman D, Aubakirova M, Nabidollayeva F, Abdildin YG. The Analysis of Multiple Outcomes between General and Regional Anesthesia in Hip Fracture Surgery: A Systematic

Review and Meta-Analysis of Randomized Controlled Trials. *J Clin Med*. 2023 Dec 5;12(24):7513. doi: 10.3390/jcm12247513. PMID: 38137582; PMCID: PMC10743918.

88. Gliedt JA, Daniels CJ, Wuollet A. Narrative Review of Perioperative Acupuncture for Clinicians. *J Acupunct Meridian Stud*. 2015 Oct;8(5):264-9. doi: 10.1016/j.jams.2014.12.004. Epub 2015 Jan 20. PMID: 26433805.

89. Amirshahi M, Behnamfar N, Badakhsh M, Rafiemanesh H, Keikhaie KR, Sheyback M, Sari M. Prevalence of postoperative nausea and vomiting: A systematic review and meta-analysis. *Saudi J Anaesth*. 2020 Jan-Mar;14(1):48-56. doi: 10.4103/sja.SJA\_401\_19. Epub 2020 Jan 6. PMID: 31998020; PMCID: PMC6970369.

90. Habib AS, Chen YT, Taguchi A, Hu XH, Gan TJ. Postoperative nausea and vomiting following inpatient surgeries in a teaching hospital: a retrospective database analysis. *Curr Med Res Opin*. 2006 Jun;22(6):1093-9. doi: 10.1185/030079906X104830. PMID: 16846542.

91. Gillion V, Jadoul M, Devuyst O, Pochet JM. The patient with metabolic alkalosis. *Acta Clin Belg*. 2019 Feb;74(1):34-40. doi: 10.1080/17843286.2018.1539373. Epub 2018 Oct 27. PMID: 30369299.

92. Gan TJ, Meyer TA, Apfel CC, Chung F, Davis PJ, Habib AS, Hooper VD, Kovac AL, Kranke P, Myles P, Philip BK, Samsa G, Sessler DI, Temo J, Tramèr MR, Vander Kolk C, Watcha M; Society for Ambulatory Anesthesia. Society for Ambulatory Anesthesia guidelines for the management of postoperative nausea and vomiting. *Anesth Analg*. 2007 Dec;105(6):1615-28, table of contents. doi: 10.1213/01.ane.0000295230.55439.f4. PMID: 18042859.

93. Wang D, Long YQ, Sun Y, Zhu YJ, Feng XM, Liu H, Ji FH, Peng K. Opioid-free total intravenous anesthesia for thyroid and parathyroid surgery: Protocol for a randomized, double-blind, controlled trial. *Front Med (Lausanne)*. 2022 Aug 30;9:939098. doi: 10.3389/fmed.2022.939098. PMID: 36111120; PMCID: PMC9468489.



94. Chidambaran V, Costandi A, D'Mello A. Propofol: a review of its role in pediatric anesthesia and sedation. *CNS Drugs*. 2015 Jul;29(7):543-63. doi: 10.1007/s40263-015-0259-6. Erratum in: *CNS Drugs*. 2018 Sep;32(9):873. PMID: 26290263; PMCID: PMC4554966.
95. Weren M, Demeere JL. Methylprednisolone vs. dexamethasone in the prevention of postoperative nausea and vomiting: a prospective, randomised, double-blind, placebo-controlled trial. *Acta Anaesthesiol Belg*. 2008;59(1):1-5. PMID: 18468010.
96. Massoth C, Schwellenbach J, Saadat-Gilani K, Weiss R, Pöpping D, Küllmar M, Wenk M. Impact of opioid-free anaesthesia on postoperative nausea, vomiting and pain after gynaecological laparoscopy - A randomised controlled trial. *J Clin Anesth*. 2021 Dec;75:110437. doi: 10.1016/j.jclinane.2021.110437. Epub 2021 Jul 3. PMID: 34229292.
97. Beloeil H, Garot M, Lebuffe G, Gerbaud A, Bila J, Cuvillon P, Dubout E, Oger S, Nadaud J, Bécrot A, Coullier N, Lecoœur S, Fayon J, Godet T, Mazerolles M, Atallah F, Sigaut S, Choinier PM, Asehnoune K, Roquilly A, Chanques G, Esvan M, Futier E, Laviolle B; POFA Study Group; SFAR Research Network. Balanced Opioid-free Anesthesia with Dexmedetomidine versus Balanced Anesthesia with Remifentanyl for Major or Intermediate Noncardiac Surgery. *Anesthesiology*. 2021 Apr 1;134(4):541-551. doi: 10.1097/ALN.0000000000003725. PMID: 33630043.
98. Janicki PK, Sugino S. Genetic factors associated with pharmacotherapy and background sensitivity to postoperative and chemotherapy-induced nausea and vomiting. *Exp Brain Res*. 2014 Aug;232(8):2613-25. doi: 10.1007/s00221-014-3968-z. Epub 2014 May 4. PMID: 24792505.
99. Gloor Y, Czarnetzki C, Curtin F, Gil-Wey B, Tramèr MR, Desmeules JA. Genetic Susceptibility Toward Nausea and Vomiting in Surgical Patients. *Front Genet*. 2022 Jan 31;12:816908. doi: 10.3389/fgene.2021.816908. PMID: 35173765; PMCID: PMC8842269.

100. Pusch F, Freitag H, Goll V, Wildling E, Hoerauf K, Obwegeser R, Weinstabl C. Electrical stimulation of the vestibular system prevents postoperative nausea and vomiting. *Acta Anaesthesiol Scand.* 2000 Oct;44(9):1145-8. doi: 10.1034/j.1399-6576.2000.440919.x. PMID: 11028738.

## Biography

Amanda Lynn LaBar was born in Tualatin, Oregon, on March 22, 1995. Amanda was raised in Wilsonville, Oregon, where she graduated from Wilsonville High School in 2013. Graduating with Cum Laude honors, Amanda received a Bachelor of Science degree in Health Sciences from Boise State University in 2017. After receiving her Bachelor of Science from Boise State University, Amanda attended the University of Zagreb School of Medicine in Zagreb, Croatia. Amanda is now in her final year of studies, nearing the completion of her medical studies at the University of Zagreb School of Medicine. Throughout her life, Amanda has actively engaged in volunteer work with various hospitals in Idaho and Oregon. Amanda's involvement within rural areas has provided her with hands-on experience, aligning with her aspirations to practice in rural medicine.